BriaCell Therapeutics Corp.

DB:8BT Stock Report

Market Cap: €24.5m

BriaCell Therapeutics Management

Management criteria checks 3/4

BriaCell Therapeutics' CEO is Bill Williams, appointed in Oct 2016, has a tenure of 8.17 years. total yearly compensation is $1.08M, comprised of 68.2% salary and 31.8% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth €77.30K. The average tenure of the management team and the board of directors is 8.2 years and 5.8 years respectively.

Key information

Bill Williams

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage68.2%
CEO tenure8.2yrs
CEO ownership0.3%
Management average tenure8.2yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bill Williams's remuneration changed compared to BriaCell Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Oct 31 2024n/an/a

-US$17m

Jul 31 2024US$1mUS$734k

-US$5m

Apr 30 2024n/an/a

-US$6m

Jan 31 2024n/an/a

-US$13m

Oct 31 2023n/an/a

-US$13m

Jul 31 2023US$1mUS$737k

-US$20m

Apr 30 2023n/an/a

-US$18m

Jan 31 2023n/an/a

-US$23m

Oct 31 2022n/an/a

-US$412k

Jul 31 2022US$811kUS$561k

-US$27m

Apr 30 2022n/an/a

-US$42m

Jan 31 2022n/an/a

-US$30m

Oct 31 2021n/an/a

-US$41m

Jul 31 2021US$830kUS$218k

-US$14m

Apr 30 2021n/an/a

US$2m

Jan 31 2021n/an/a

-US$2m

Oct 31 2020n/an/a

-US$3m

Jul 31 2020US$231kUS$231k

-US$4m

Apr 30 2020n/an/a

-US$4m

Jan 31 2020n/an/a

-US$5m

Oct 31 2019n/an/a

-US$5m

Aug 01 2019n/an/a

-US$5m

Apr 30 2019n/an/a

-US$5m

Jan 31 2019n/an/a

-US$5m

Oct 31 2018n/an/a

-US$4m

Jul 31 2018US$228kUS$175k

-US$4m

Compensation vs Market: Bill's total compensation ($USD1.08M) is above average for companies of similar size in the German market ($USD469.36K).

Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.

CEO

Bill Williams (69 yo)

8.2yrs

Tenure

US$1,077,070

Compensation

Dr. William V. Williams, M.D., FRCP, also known as Bill, has been the Chief Executive Officer and President of BriaCell Therapeutics Corp. since October 2016 and serves as its Director Since November 1, 20...

Leadership Team

NamePositionTenureCompensationOwnership
William Williams
CEO, President & Director8.2yrsUS$1.08m0.32%
€ 77.3k
Gadi Levin
CFO & Corporate Secretary8.8yrsUS$520.73k0.0064%
€ 1.6k
Miguel Lopez-Lago
Chief Scientific Officer2.6yrsUS$393.61k0%
€ 0
Giuseppe Del Priore
Chief Medical Officer2.8yrsUS$780.85k0%
€ 0
Charles Wiseman
Founder9.5yrsUS$241.14kno data

8.2yrs

Average Tenure

62yo

Average Age

Experienced Management: 8BT's management team is seasoned and experienced (8.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Williams
CEO, President & Director8.1yrsUS$1.08m0.32%
€ 77.3k
Charles Wiseman
Founder3.9yrsUS$241.14kno data
Brian Metcalf
Member of Scientific Advisory Board7.6yrsno datano data
Martin Schmieg
Independent Director4.1yrsUS$166.86k0%
€ 0
Rebecca Taub
Independent Director5.8yrsUS$141.87k0%
€ 0
Vaughn Embro-Pantalony
Lead Independent Director5.8yrsUS$175.88k0.033%
€ 8.0k
Douglas Faller
Member of Scientific Advisory Board7.6yrsno datano data
Jane Gross
Independent Director2.9yrsUS$146.86k0%
€ 0
Thomas Kieber-Emmons
Member of Scientific Advisory Board7.6yrsno datano data
Maria Trojanowska
Member of Scientific Advisory Board7.6yrsno datano data
Jamieson Bondarenko
Independent Chairman of the Board5.8yrsUS$664.11k0.27%
€ 66.3k
Cara Haymaker
Member of Scientific Advisory Board5.3yrsno datano data

5.8yrs

Average Tenure

68.5yo

Average Age

Experienced Board: 8BT's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/10/31
Annual Earnings2024/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BriaCell Therapeutics Corp. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.
Ashok KumarThinkEquity LLC